BBD Longitudinal Study of Osteogenesis Imperfecta

NCT02432625 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2025-08-13

No results posted yet for this study

Summary

Osteogenesis Imperfecta (OI) is a rare disorder of increased bone fragility characterized by fractures with minimal or absent trauma, dentinogenesis imperfecta (DI), and, in adult years, hearing loss. It is seen in both genders and all races. The clinical features of OI represent a continuum varying from perinatal lethality to individuals with severe skeletal deformities, mobility impairments, and very short stature to nearly asymptomatic individuals with a mild predisposition to fractures, normal stature, and normal lifespan. Fractures can occur in any bone, but are most common in the extremities. These disorders can be devastating and progressive and result in deformity, chronic pain, impaired function and loss of quality of life.

The overall goal of this study is to answer specific question about the natural history of brittle bone diseases as defined by molecular etiology and to develop the foundation for prospective clinical studies.

Conditions

Sponsors & Collaborators

  • Shriners Hospitals for Children

    collaborator OTHER
  • Hospital for Special Surgery, New York

    collaborator OTHER
  • Children's National Research Institute

    collaborator OTHER
  • Hugo W. Moser Research Institute at Kennedy Krieger, Inc.

    collaborator OTHER
  • University of California, Los Angeles

    collaborator OTHER
  • Oregon Health and Science University

    collaborator OTHER
  • University of Nebraska

    collaborator OTHER
  • Alfred I. duPont Hospital for Children

    collaborator OTHER
  • University of South Florida

    collaborator OTHER
  • Phoenix Children's Hospital

    collaborator OTHER
  • Marquette University

    collaborator OTHER
  • Baylor College of Medicine

    lead OTHER

Principal Investigators

  • V. Reid Sutton, M.D. · Baylor College of Medicine

  • Frank Rauch, M.D. · McGill University

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-06-01
Primary Completion
2030-08-31
Completion
2031-12-31

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02432625 on ClinicalTrials.gov